华东医药DR10624注射液药品临床试验申请获美国FDA批准

Core Viewpoint - Huadong Medicine's subsidiary, Zhejiang Daer Biotechnology Co., Ltd., has received FDA approval for clinical trials of its drug DR10624 in the U.S., targeting severe hypertriglyceridemia [1] Company Summary - Huadong Medicine announced that its subsidiary, Zhejiang Daer Biotechnology, has successfully obtained FDA approval for the clinical trial application of DR10624 injection [1] - The approved indication for DR10624 is severe hypertriglyceridemia, a condition characterized by high levels of triglycerides in the blood [1] Industry Summary - The approval from the FDA allows for the commencement of clinical trials in the U.S., which is a significant step for the company in the biopharmaceutical sector [1]